GPX4 Inhibitor Screening Assay Kit Reference: 701880-96 Cayman's GPX4 Inhibitor Screening Assay Kit provides a robust and easy-to-use platform for identifying novel inhibitors of human GPX4, a negative regulator of the ferroptosis pathway. The assay measures GPX4 indirectly by a coupled reaction with glutathione reductase (GR). Oxidized glutathione (GSSG), produced upon reduction of hydroperoxide by GPX4, is recycled to its reduced state by GR and NADPH. The oxidation of NADPH to NADP+ is accompanied by a decrease in absorbance at 340 nm. The rate of decrease in A340 is directly proportional to GPX4 activity. The GPX4 inhibitor ML-162 is included as a positive control
Caspase-6 Inhibitor Screening Assay Kit Reference: 701890-384 Cayman’s Caspase-6 Inhibitor Screening Assay Kit provides a robust and easy-to-use platform for identifying novel inhibitors of human caspase-6, a cysteine protease implicated in multiple neurodegenerative disorders. The assay uses a caspase-6-specific fluorogenic substrate, Z-VEID-AFC. Caspase-6 cleaves this substrate generating free AFC, which can be easily quantified using a fluorescence plate reader at excitation and emission wavelengths of 400 and 505 nm, respectively. The potent and reversible caspase-6 inhibitor Ac-VEID-CHO is included as a positive control and inhibits caspase-6 with an IC50 value of 12 nM.
FSP1 Fluorescent Inhibitor Screening Assay Kit Reference: 701900-384 Cayman's FSP1 Fluorescent Inhibitor Screening Assay Kit provides a robust and easy-to-use platform for identifying novel inhibitors of human FSP1, a negative regulator of the ferroptosis pathway. The assay measures the reduction of resazurin by FSP1 into resorufin, which can be easily quantified using a fluorescence plate reader at excitation and emission wavelengths of 540 and 590 nm, respectively. The potent and reversible FSP1 inhibitor iFSP1 is included as a positive control and inhibits FSP1 with an IC50 value of 267 ± 47 nM.